Vismodegib as Eye-Sparing Adjuvant Treatment for Orbital Basal Cell Carcinoma
Orbital invasion of basal cell carcinoma (BCC) may lead to disfigurement, blindness, or even death. 1 Orbital exenteration, although disfiguring and blinding, is often the only option for cure when incompletely excised medial canthal tumors extend into the orbit. 2 The US Food and Drug Administration has recently approved a hedgehog pathway inhibitor 3 with an adequate safety profile, 4 vismodegib (Erivedge), for oral treatment of basal cell nevus syndrome 5 and locally advanced or metastatic BCC. 6 We describe a patient with BCC invading the The area in the white squares (A and C) has been analyzed with adaptive optics imaging. Color photographs show pigmented spots (E), some of which are hyperautofluorescent on fundus autofluorescence imaging (F). These spots correspond to the numerous dark spots detected on adaptive optics imaging, which are distributed along the choroidal vessels (G).
Letters medial orbit who was treated with oral vismodegib, resulting in near-total tumor shrinkage that permitted complete excision with clear surgical margins. Histopathologically, the excised tissue contained scattered residual tumor cells exhibiting squamous differentiation and low proliferative capacity.
Report of a Case | A 79-year-old man developed left lower eyelid retraction 10 years after BCC excision. Examination demonstrated normal vision, limited left ductions, increased left tear lake, and left medial canthal fullness but no external skin lesion. Biopsy revealed aggressive-growth-pattern BCC (ie, morpheaform, with irregular strands of deeply invading cells) ( Figure 1B and C). Following biopsy, magnetic resonance imaging showed a 2.7 × 1.6 × 1.9-cm medial orbital mass ( Figure 1A ). To avoid exenteration with loss of the eye, medical treatment with vismodegib, 150 mg/d by mouth, was begun 1 month later. During the next 5 months, the patient reported occasional nausea and diarrhea and progressively worsening muscle spasms-all known adverse effects of vismodegib therapy. 4 Magnetic resonance imaging after 4 months of treatment showed reduction in tumor size to 0.7 × 0.7 × 0.5 cm ( Figure 1D ). Because of painful muscle spasms, the patient opted for surgical excision instead of continued vismodegib therapy. En bloc excision of the residual orbital mass was performed along with medial rectus muscle release using frozen-section control. Postfixation histopathologic evaluation revealed all margins to be clear of tumor. Vismodegib was discontinued at surgery. The patient has done well, with complete resolution of treatment adverse effects, including the muscle spasms, within 2 months of treatment cessation.
The excised tumor was submitted in toto and fully analyzed in sequential sections. The original, highly cellular, aggressive-growth-pattern BCC, with areas of squamous differentiation, stained positive for high-molecular-weight cytokeratin. The excised, treated mass revealed a reduction in tumor load ( Figure 1B and C vs Figure 1E and F) with the vast majority of tissue composed of fibrotic and fibrovascular tissue with mild, scattered acute and chronic inflammation (Figure 2A and B) . Single or small clusters of cytokeratin-positive cells with squamous differentiation, vesicular or smudged nuclei, and abundant eosinophilic cytoplasm were scattered multifocally in the fibrous matrix ( Figure 2D ). Foci of degenerating squamous cell clusters infiltrated by histiocytes ( Figure 2E ) and clusters of tumor ghost cells lacking nuclei ( Figure 2C ) were also present. Many infiltrating leukocytes were immunoreactive for the macrophage marker CD68 ( Figure 2F) . Importantly, the residual squamous cells not only exhibited degenerative cytologic features but also failed to exhibit nuclear immunoreactivity for the proliferation marker Ki-67 ( Figure 2I ), suggesting virtual loss of tumor cell proliferation (mitotic index <1%) following vismodegib treatment, in stark contrast to the original BCC ( Figure 2G ).
Discussion | Oral vismodegib is a novel therapy for the treatment of metastatic or locally advanced and organthreatening BCC and may be considered for treatment of eligible patients with eye-threatening orbital BCC. Because the drug is newly approved and is associated with a range of adverse effects and health risks, 4 additional experience and ) and degenerative nests (original magnification ×200) (C) with a lymphocytic infiltrate (original magnification ×200) (D). Leukocyte phagocytosis of degenerated cells is noted on hematoxylin-eosin staining (original magnification ×100) (E) and CD68 immunohistochemistry (original magnification ×100) (F). In contrast to a high pretreatment proliferative index as indicated by extensive nuclear immunostaining for Ki67 (original magnification ×100) (G), posttreatment tumor shows virtual absence of immunoreactivity (original magnification ×100) (I, representing the only area of the excised tumor with any hint of Ki67 staining). Histologic analysis of corresponding adjacent sections was performed with hematoxylin-eosin staining (original magnification ×100) (H and J).
